{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T23:10:06Z","timestamp":1784675406959,"version":"3.55.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,4,23]],"date-time":"2018-04-23T00:00:00Z","timestamp":1524441600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Research Fund of the China-Japan Friendship Hospital","award":["2013-RC-3"],"award-info":[{"award-number":["2013-RC-3"]}]},{"name":"Foundation of capital characteristic clinical application research","award":["2106-BKJ-004"],"award-info":[{"award-number":["2106-BKJ-004"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12883-018-1056-x","type":"journal-article","created":{"date-parts":[[2018,4,23]],"date-time":"2018-04-23T02:21:39Z","timestamp":1524450099000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Dose effects of mycophenolate mofetil in Chinese patients with neuromyelitis optica spectrum disorders: a case series study"],"prefix":"10.1186","volume":"18","author":[{"given":"Yujuan","family":"Jiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihe","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeqiong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0194-5690","authenticated-orcid":false,"given":"Jinsong","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,4,23]]},"reference":[{"issue":"5","key":"1056_CR1","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1212\/WNL.53.5.1107","volume":"53","author":"DM Wingerchuk","year":"1999","unstructured":"Wingerchuk DM, Hogancamp WF, O\u2019Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic\u2019s syndrome). Neurology. 1999;53(5):1107\u201314.","journal-title":"Neurology"},{"issue":"8","key":"1056_CR2","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1212\/01.wnl.0000254502.87233.9a","volume":"68","author":"DM Wingerchuk","year":"2007","unstructured":"Wingerchuk DM, Pittock SJ, Lucchinetti CF, Lennon VA, Weinshenker BG. A secondary progressive clinical course is uncommon in neuromyelitis optica. Neurology. 2007;68(8):603\u20135.","journal-title":"Neurology"},{"issue":"3","key":"1056_CR3","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1001\/jamaneurol.2013.5699","volume":"71","author":"MA Mealy","year":"2014","unstructured":"Mealy MA, Wingerchuk DM, Palace J, Greenberg BM, Levy M. Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. JAMA Neurol. 2014;71(3):324\u201330.","journal-title":"JAMA Neurol."},{"issue":"9","key":"1056_CR4","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1001\/archneurol.2009.175","volume":"66","author":"A Jacob","year":"2009","unstructured":"Jacob A, Matiello M, Weinshenker BG, Wingerchuk DM, Lucchinetti C, Shuster E, et al. Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol. 2009;66(9):1128\u201333.","journal-title":"Arch Neurol"},{"issue":"11","key":"1056_CR5","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1001\/jamaneurol.2014.2057","volume":"71","author":"SY Huh","year":"2014","unstructured":"Huh SY, Kim SH, Hyun JW, Joung AR, Park MS, Kim BJ, et al. Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder. JAMA Neurol. 2014;71(11):1372\u20138.","journal-title":"JAMA Neurol"},{"issue":"2","key":"1056_CR6","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1097\/WNF.0000000000000131","volume":"39","author":"H Chen","year":"2016","unstructured":"Chen H, Zhang Y, Shi Z, Feng H, Yao S, Xie J, et al. The efficacy and tolerability of mycophenolate Mofetil in treating Neuromyelitis Optica and Neuromyelitis Optica Spectrum disorder in western China. Clin Neuropharmacol. 2016;39(2):81\u20137.","journal-title":"Clin Neuropharmacol"},{"key":"1056_CR7","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.jns.2016.09.035","volume":"370","author":"Y Xu","year":"2016","unstructured":"Xu Y, Wang Q, Ren HT, Qiao L, Zhang Y, Fei YY, et al. Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and cyclophosphamide among patients with neuromyelitis optica spectrum disorder: a prospective cohort study. J Neurol Sci. 2016 Nov 15;370:224\u20138.","journal-title":"J Neurol Sci"},{"issue":"1","key":"1056_CR8","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/ene.13186","volume":"24","author":"H Chen","year":"2017","unstructured":"Chen H, Qiu W, Zhang Q, Wang J, Shi Z, Liu J, et al. Comparisons of the efficacy and tolerability of mycophenolate mofetil and azathioprine as treatments for neuromyelitis optica and neuromyelitis optica spectrum disorder. Eur J Neurol. 2017;24(1):219\u201326.","journal-title":"Eur J Neurol"},{"issue":"3","key":"1056_CR9","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1177\/1352458515587752","volume":"22","author":"IH Jeong","year":"2016","unstructured":"Jeong IH, Park B, Kim SH, Hyun JW, Joo J, Kim HJ. Comparative analysis of treatment outcomes in patients with neuromyelitis optica spectrum disorder using multifaceted endpoints. Mult Scler J. 2016;22(3):329\u201339.","journal-title":"Mult Scler J"},{"issue":"10","key":"1056_CR10","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1177\/1352458516678474","volume":"23","author":"A Montcuquet","year":"2017","unstructured":"Montcuquet A, Collongues N, Papeix C, Zephir H, Audoin B, Laplaud D, et al. NOMADMUS study group and the Observatoire Fran\u00e7ais de la Scl\u00e9rose en plaques (OFSEP). Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders. Mult Scler. 2017;23(10):1377\u201384.","journal-title":"Mult Scler"},{"key":"1056_CR11","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","volume":"66","author":"DM Wingerchuk","year":"2006","unstructured":"Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006;66:1485\u20139.","journal-title":"Neurology"},{"issue":"9","key":"1056_CR12","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","volume":"6","author":"DM Wingerchuk","year":"2007","unstructured":"Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol. 2007;6(9):805\u201315.","journal-title":"Lancet Neurol"},{"key":"1056_CR13","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.msard.2016.02.014","volume":"7","author":"G Tackley","year":"2016","unstructured":"Tackley G, O\u2019Brien F, Rocha J, Woodhall M, Waters P, Chandratre S, et al. Neuromyelitis optica relapses: race and rate, immunosuppression and impairment. Mult Scler Relat Disord. 2016;7:21\u20135.","journal-title":"Mult Scler Relat Disord"},{"key":"1056_CR14","volume-title":"Communication about an ongoing safety review of CellCept (mycophenolate mofetil) and Myfortic (mycophenolic acid)","author":"US Food and Drug Administration","year":"2015","unstructured":"US Food and Drug Administration. Communication about an ongoing safety review of CellCept (mycophenolate mofetil) and Myfortic (mycophenolic acid). Rockville, MD: US Food and Drug Administration; 2015."},{"issue":"2","key":"1056_CR15","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1590\/S0482-50042012000200013","volume":"52","author":"SC Fialho","year":"2012","unstructured":"Fialho SC, Bergamaschi S, Neves FS, Zimmermann AF, Castro GR, Pereira IA. Mycophenolate mofetil in primary Sj\u00f6gren's syndrome: a treatment option for agranulocytosis. Rev Bras Reumatol. 2012;52(2):297\u20139.","journal-title":"Rev Bras Reumatol"},{"issue":"4","key":"1056_CR16","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1097\/FTD.0000000000000031","volume":"36","author":"S Alexander","year":"2014","unstructured":"Alexander S, Fleming DH, Mathew BS, Varughese S, Jeyaseelan V, Tamilarasi V, et al. Pharmacokinetics of concentration-controlled mycophenolate mofetil in proliferative lupus nephritis: an observational cohort study. Ther Drug Monit. 2014;36(4):423\u201332.","journal-title":"Ther Drug Monit"},{"issue":"3","key":"1056_CR17","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1177\/0961203313519158","volume":"23","author":"C Lourdudoss","year":"2014","unstructured":"Lourdudoss C, Vollenhoven RV. Mycophenolate mofetil in the treatment of SLE and systemic vasculitis: experience at a single university center. Lupus. 2014;23(3):299\u2013304.","journal-title":"Lupus"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-018-1056-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12883-018-1056-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-018-1056-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,22]],"date-time":"2019-04-22T19:13:23Z","timestamp":1555960403000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-018-1056-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,23]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1056"],"URL":"https:\/\/doi.org\/10.1186\/s12883-018-1056-x","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,23]]},"assertion":[{"value":"24 September 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Medical Ethics Committee of China-Japan Friendship Hospital. The reference number is: 2016\u201362. Written informed consents were obtained from all the participants or his\/her parents\/legal representatives (for participant under 18\u00a0years old).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"47"}}